Highlights

  • 4DMedical received TGA approval for CT:VQ™, enabling commercial deployment across Australia and adding to existing approvals in major global markets.
  • The technology is now cleared across the United States, EU, UK, Canada, New Zealand, and Australia, strengthening its regulatory foundation.
  • The company is progressing a Medicare reimbursement pathway (MSAC submission) while leveraging U.S. clinical adoption at major hospital networks.

4DMedical Limited (ASX:4DX) has reached a significant regulatory milestone with the approval of its CT:VQ™ imaging software by the Therapeutic Goods Administration (TGA), enabling commercial deployment across Australia. The announcement comes as the company’s shares traded at AUD 4.42, reflecting a 3.28% decline during the session.

The approval represents an important expansion of the company’s global regulatory footprint and supports its broader strategy of commercialising software-based respiratory imaging across multiple healthcare systems.

Share Price Movement Occurs Amid Regulatory Expansion

The intraday decline in 4DMedical’s share price occurred despite the release of a material regulatory update. In medical technology markets, short-term price movements are often influenced by broader risk sentiment and liquidity conditions rather than isolated operational milestones.

However, regulatory approvals such as TGA clearance typically serve as foundational steps for commercial rollout rather than immediate revenue acceleration. As such, market interpretation tends to focus on the timing and scale of future reimbursement and adoption pathways rather than the approval event itself.

CT:VQ™ Gains Nationwide Commercial Clearance in Australia

The central development is the inclusion of CT:VQ™ on the Australian Register of Therapeutic Goods (ARTG), effectively allowing clinical use across hospitals and imaging centres in Australia.

CT:VQ™ is a software-only, non-contrast ventilation-perfusion imaging solution that derives functional lung imaging data from standard CT scans. Unlike traditional nuclear medicine-based ventilation-perfusion scans, it does not require radiotracers, contrast agents, or specialised nuclear imaging infrastructure.

This positions the technology as a potential alternative in respiratory diagnostics, particularly in healthcare systems seeking to reduce reliance on nuclear medicine capacity.

Global Regulatory Footprint Continues to Expand

With the TGA approval, CT:VQ™ now holds regulatory clearance across several major healthcare markets, including the United States, European Union, United Kingdom, Canada, New Zealand, and Australia.

The company’s regulatory strategy has focused on achieving multi-jurisdictional approvals to support clinical adoption and reimbursement discussions across diverse healthcare systems. Each approval adds to the clinical validation framework and supports physician familiarity with the technology.

Earlier regulatory clearance in the United States, followed by deployment in leading academic medical centres, has played a key role in building clinical reference data and supporting international adoption discussions.

U.S. Adoption Provides Early Commercial Validation

Momentum in the United States has been a key reference point for 4DMedical’s global strategy. Following FDA clearance in September 2025, CT:VQ™ has been deployed across several major healthcare institutions, including Stanford, Cleveland Clinic, UC San Diego Health, University of Chicago Medicine, and University of Miami.

Evaluation is also underway at Mayo Clinic, which is widely regarded as a significant validation site in global medical technology adoption cycles.

In parallel, the company has expanded into community-based imaging through its commercial agreement with SimonMed Imaging, one of the largest outpatient radiology providers in the United States. This development extends CT:VQ™ beyond academic settings into high-volume clinical workflows.

Australian Healthcare Infrastructure Supports Adoption Potential

Australia presents a structurally supportive environment for CT:VQ™ deployment due to its high density of CT imaging infrastructure. With more than 74 CT scanners per million people, Australia ranks among the highest globally in CT availability.

This infrastructure base reduces reliance on nuclear medicine facilities and enables broader distribution of functional lung imaging capabilities across metropolitan, regional, and rural healthcare settings.

The company has highlighted several potential use cases, including regional hospitals without nuclear medicine access, imaging centres lacking specialised radiotracer capability, and healthcare systems seeking to reduce exposure to radioactive materials.

Pathway Toward Medicare Reimbursement

A key commercial milestone following TGA approval is the planned submission to the Medical Services Advisory Committee (MSAC) in pursuit of Medicare Benefits Schedule (MBS) reimbursement.

Reimbursement is typically a critical driver of adoption in publicly funded healthcare systems, as it determines whether a diagnostic procedure is financially supported at scale.

The submission will include clinical evidence, health-economic modelling, and real-world utilisation data derived from both Australian and international deployments. The outcome of this process will play a central role in determining the pace of domestic adoption.

SaaS-Based Medical Imaging Model

4DMedical operates a software-as-a-service (SaaS) model, integrating its imaging solutions into existing hospital infrastructure. This approach reduces the need for large capital equipment installations and enables deployment through software integration into existing CT systems.

The company’s broader product portfolio includes XV LVAS®, CT LVAS™, and CT:VQ™, supported by artificial intelligence capabilities acquired through Imbio and contextflow.

This model aligns with broader trends in healthcare digitisation, where software-driven diagnostics are increasingly used to enhance existing imaging workflows rather than replace core imaging hardware.

Clinical Positioning in Respiratory Diagnostics

CT:VQ™ is positioned as a functional lung imaging tool designed to assist in the assessment of ventilation and perfusion distribution within the lungs. By deriving functional data from standard CT scans, it aims to provide clinicians with additional diagnostic information without the procedural complexity of traditional nuclear medicine tests.

The clinical utility of such systems is increasingly relevant in respiratory medicine, particularly in chronic lung disease, pulmonary embolism evaluation, and pre-operative assessment contexts.

Conclusion

4DMedical’s TGA approval for CT:VQ™ represents a key regulatory milestone that expands its commercial addressable market into Australia, complementing existing approvals across major global healthcare jurisdictions. While the immediate share price reaction reflected broader market conditions, the strategic significance lies in the establishment of a multi-market regulatory foundation and the progression toward reimbursement in both Australia and the United States. With growing clinical adoption in leading U.S. institutions and a structured pathway toward Medicare reimbursement, CT:VQ™ continues to evolve as a globally positioned software-based respiratory imaging platform, with its near-term trajectory dependent on clinical uptake and reimbursement outcomes across key healthcare systems.